Intellia Therapeutics, Inc. (LON: 0JBU)
London
· Delayed Price · Currency is GBP · Price in USD
11.10
+0.79 (7.66%)
Jan 23, 2025, 12:04 PM BST
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $9.11M USD in the quarter ending September 30, 2024, a decrease of -24.02%. This brings the company's revenue in the last twelve months to $43.09M, down -16.77% year-over-year. In the year 2023, Intellia Therapeutics had annual revenue of $36.28M, down -30.40%.
Revenue (ttm)
$43.09M
Revenue Growth
-16.77%
P/S Ratio
n/a
Revenue / Employee
$81.91K
Employees
526
Market Cap
910.48M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
Dec 31, 2019 | 43.10M | 12.67M | 41.63% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Intellia Therapeutics News
- 2 days ago - NTLA ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Intellia Therapeutics, Inc. investment - Accesswire
- 2 days ago - Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 3 days ago - Levi & Korsinsky Investigates Possible Securities Fraud Violations by Intellia Therapeutics, Inc. (NTLA) - Accesswire
- 3 days ago - NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Intellia Therapeutics, Inc. and Encourages Investors to Contact the Firm - Accesswire
- 4 days ago - Lost Money on Intellia Therapeutics, Inc.(NTLA)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - Accesswire
- 4 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intellia Therapeutics, Inc - NTLA - Accesswire
- 5 days ago - Editas And Intellia: Strategic Shifts And Long-Term Investment Potential - Seeking Alpha
- 5 days ago - Intellia Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - NTLA - Accesswire